@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA8577 pubblicazioni:autoreCNRDi prodotto:ID209701 . unitaDiPersonaleInterno:MATRICOLA11 pubblicazioni:autoreCNRDi prodotto:ID209701 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS061 prodottidellaricerca:prodotto prodotto:ID209701 . @prefix rdf: . prodotto:ID209701 rdf:type prodotto:TIPO1101 . @prefix retescientifica: . prodotto:ID209701 rdf:type retescientifica:ProdottoDellaRicerca . @prefix rdfs: . prodotto:ID209701 rdfs:label "The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID209701 pubblicazioni:anno "2013-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1016/j.diabet.2013.02.003"^^xsd:string . @prefix skos: . prodotto:ID209701 skos:altLabel "
S. MAGGI (1); M. NOALE (1); A. PILOTTO (2); A. TIENGO (3); P. CAVALLO PERIN (4); G. CREPALDI (1) FOR THE METABOLIC WORKING GROUP (2013)
The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment.
in Diabetes & metabolism (Online); Elsevier Masson SAS, Issy les Moulineaux (Francia)
"^^rdf:HTML ; pubblicazioni:autori "S. MAGGI (1); M. NOALE (1); A. PILOTTO (2); A. TIENGO (3); P. CAVALLO PERIN (4); G. CREPALDI (1) FOR THE METABOLIC WORKING GROUP"^^xsd:string . @prefix ns10: . prodotto:ID209701 pubblicazioni:rivista ns10:ID112433 ; skos:note "PubMe"^^xsd:string ; pubblicazioni:affiliazioni "(1) CNR - Institute of Neuroscience, Aging Branch, via Giustiniani 2, 35128 Padua, Italy \n(2) Geriatric Department, Health Unit 16, Padua, Italy \n(3) Department of Medicine, University of Padua, Padua, Italy \n(4) Diabetology Unit, University of Turin, Turin, Italy"^^xsd:string ; pubblicazioni:titolo "The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment."^^xsd:string ; prodottidellaricerca:abstract "Abstract\nAIM:\nThe objective of the METABOLIC Study was to evaluate overall health status, with particular focus on assessment of functional status of older patients taking oral antidiabetic drug (OAD) treatment.\nMETHODS:\nThe study included 1342 type 2 diabetes patients aged>=65years treated with OADs, with or without insulin, who had been referred to outpatients clinics across Italy. Information on diabetes (duration, medications taken during the last 3months, hypoglycaemic events and diabetic complications) was collected by questionnaire, and the patients' overall health status was assessed using a multidimensional prognostic index.\nRESULTS:\nThe sample recruited (mean age: 73.3\u00B15.5years) had a mean duration of diabetes of 11.3\u00B18.2years. Half were taking sulphonylureas alone or together with other medications, 9.7% were taking insulin in combination with other OADs, almost 30% were using biguanides and 6.2% were taking dipeptidyl peptidase-4 (DPP-4) inhibitors. Also, 12% of patients reported hypoglycaemic events, 90% of whom were taking insulin or sulphonylureas. In addition, 81% of the participants were completely independent in their activities of daily living, while 19% were mildly, moderately or severely disabled. Age, female gender, hypoglycaemic events, neuropathy and low diastolic blood pressure were the main variables associated with disability.\nCONCLUSION:\nDisability is common in older diabetic patients and some associated factors, such as hypoglycaemia and low diastolic blood pressure, have been identified. Also identified was malnutrition as a specific factor associated with hypoglycaemic events independent of the use of insulin and sulphonylureas."@en , "R\u00E9sum\u00E9\n\u00C9tude METABOLIC : une \u00E9valuation multidimensionnelle de l'\u00E9tat de sant\u00E9 et de capacit\u00E9s fonctionnelles des patients \u00E2g\u00E9s atteints de diab\u00E8te de type 2, en traitement antidiab\u00E9tique oral.\n\nL'objectif de l'\u00E9tude\nMETABOLIC est l'\u00E9valuation de l'\u00E9tat de sant\u00E9 global des patients \u00E2g\u00E9s atteints de diab\u00E8te de type 2, en traitement antidiab\u00E9tique oral, avec une attention particuli\u00E8re pour l'\u00E9valuation de capacit\u00E9s fonctionnelles.\n\nM\u00E9thodes\nL'\u00E9tude comprend 1342 patients diab\u00E9tiques de type 2 \u00E2g\u00E9s de 65ans ou plus, en traitement antidiab\u00E9tique oral, avec ou sans insuline, en se r\u00E9f\u00E9rant aux centres antidiab\u00E9tiques en Italie. Informations sur le diab\u00E8te (dur\u00E9e, m\u00E9dicaments au cours des trois mois pr\u00E9c\u00E9dents, les \u00E9v\u00E9nements hypoglyc\u00E9miques, et les complications diab\u00E9tiques) ont \u00E9t\u00E9 recueillies dans un questionnaire. L'\u00E9tat de sant\u00E9 g\u00E9n\u00E9rale des patients a \u00E9t\u00E9 \u00E9valu\u00E9 par l'indicateur MPI (Multidimensional Prognostic Index).\n\nR\u00E9sultats\nLes patients inclus dans l'\u00E9tude (\u00E2ge moyen=73,3\u00B15,5ans) avaient une dur\u00E9e moyenne du diab\u00E8te de 11,3\u00B18,2ans. La moiti\u00E9 des patients \u00E9tudi\u00E9s prenaient sulfonylur\u00E9es seul ou conjointement avec d'autres m\u00E9dicaments, 9,7 % prenaient insuline en association avec d'autres traitements antidiab\u00E9tiques oraux, pr\u00E8s de 30 % prenaient les biguanides, et 6,2 % prenaient dipeptidyl-peptidase-4 (DPP-4) inhibiteurs. Douze pour cent ont signal\u00E9 des \u00E9v\u00E9nements hypoglyc\u00E9miques et environ 90 % d'entre eux \u00E9taient en traitement avec l'insuline ou les sulfonylur\u00E9es. Quatre-vingt-un pour cent de l'\u00E9chantillon \u00E9tait totalement ind\u00E9pendant dans les activit\u00E9s de la vie quotidienne, 19 % avaient une d\u00E9pendance l\u00E9g\u00E8re, mod\u00E9r\u00E9e ou s\u00E9v\u00E8re dans les activit\u00E9s quotidiennes. L'\u00E2ge, le sexe de la femelle, les \u00E9pisodes hypoglyc\u00E9miques, la neuropathie et basse pression art\u00E9rielle diastolique \u00E9taient les principales variables li\u00E9es \u00E0 l'invalidit\u00E9.\n\nConclusion\nLa perte de la fonction physique est un probl\u00E8me important de personnes \u00E2g\u00E9es atteintes de diab\u00E8te et nous avons identifi\u00E9 certains facteurs associ\u00E9s (hypoglyc\u00E9mie, faible pression art\u00E9rielle diastolique). Nous avons aussi identifi\u00E9 la malnutrition comme un facteur sp\u00E9cifique li\u00E9 aux \u00E9v\u00E9nements hypoglyc\u00E9miques, ind\u00E9pendamment de l'utilisation de l'insuline et des sulfonylur\u00E9es."@fr . @prefix ns11: . prodotto:ID209701 pubblicazioni:editore ns11:ID12986 ; prodottidellaricerca:prodottoDi istituto:CDS061 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA8577 , unitaDiPersonaleInterno:MATRICOLA11 . @prefix parolechiave: . prodotto:ID209701 parolechiave:insiemeDiParoleChiave . ns11:ID12986 pubblicazioni:editoreDi prodotto:ID209701 . ns10:ID112433 pubblicazioni:rivistaDi prodotto:ID209701 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID209701 .